Development and Regulatory Approval Application for a Combined COVID-19 and Influenza Diagnostic Kit
First written in FY2021. 2 of 6 entries say "Advanced", first in FY2023-Q3. Latest entry: FY2025-H1.
0 other companies' latest entry also says "Other".
- FY2025-H1Lower sales volume of combined diagnostic kitsAnnual report
「Meanwhile, POCT test reagents generated lower revenue because sales volume of combined COVID-19 and influenza virus diagnostic kits fell below the previous year.」
Sales volume of combined COVID-19 and influenza diagnostic kits fell below the previous year, becoming a factor behind lower revenue from POCT test reagents. - FY2024-Q3RestatedAnnual report
「POCT test reagents generated higher revenue: sales of rapid COVID-19 antigen diagnostic kits fell below the previous year, but sales of combined COVID-19 and influenza virus diagnostic kits increased amid the influenza outbreak.」
The disclosure reconfirms that the increase in sales of combined COVID-19 and influenza diagnostic kits against the backdrop of the influenza outbreak contributed to higher revenue in the diagnostic reagents segment. - FY2024-Q2AdvancedAnnual report
「POCT test reagents generated higher revenue: sales of rapid COVID-19 antigen diagnostic kits fell below the previous year, but sales of combined COVID-19 and influenza virus diagnostic kits increased amid the influenza outbreak.」
Sales of combined COVID-19 and influenza diagnostic kits increased against the backdrop of the influenza outbreak, contributing to higher revenue in the diagnostic reagents segment. - FY2024-Q1RestatedAnnual report
「Sales of combined COVID-19 and influenza virus diagnostic kits increased as the influenza outbreak persisted for longer, resulting in higher revenue.」
The disclosure reconfirms that sales of combined COVID-19 and influenza diagnostic kits increased against the backdrop of the prolonged influenza outbreak. - FY2023-Q3AdvancedAnnual report
「Shipments of rapid COVID-19 antigen diagnostic kits and combined COVID-19 and influenza virus diagnostic kits increased as demand broadened through distribution to elderly care facilities via local governments and screening tests at home and in the workplace, in addition to the spread of infections, but prices fell substantially due to lower reimbursement points, resulting in lower revenue.」
Shipments of diagnostic products, including combined COVID-19 and influenza diagnostic kits, increased as supplies expanded for distribution by local governments and testing at home and in the workplace, but lower prices resulting from reduced reimbursement points led to lower revenue. - FY2021First statedAnnual report
「In January this year, the Company developed a rapid antigen diagnostic kit capable of simultaneously diagnosing COVID-19 and influenza virus using a single device and applied for regulatory approval in Japan.」
The Company developed a rapid antigen diagnostic kit for simultaneous diagnosis of COVID-19 and influenza using a single device and applied for regulatory approval in Japan.